Litman Gregory Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Litman Gregory Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$875	Buy	+50	New	+$941	﹤0.01%	328

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PCMH

Polymer Capital Management (HK) Hong Kong $1.98B AUM 210.13% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Litman Gregory Wealth Management's SMMT Position: Q4 2025 in Review

Litman Gregory Wealth Management opened a new position in Summit Therapeutics (SMMT) in Q4 2025: 50 shares worth $875. The stake represents ﹤0.01% of the portfolio and ranks #328 among its holdings.

206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

Litman Gregory Wealth Management held 50 shares of Summit Therapeutics worth $875 as of Q4 2025.
Summit Therapeutics was a new Litman Gregory Wealth Management position in Q4 2025.
Summit Therapeutics made up ﹤0.01% of Litman Gregory Wealth Management's portfolio in Q4 2025, its #328 holding.
206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Litman Gregory Wealth Management's 13F filing for Q4 2025, filed 12 Feb 2026.